Dermata Therapeutics, Inc. (DRMA) Stock Price & Analysis
Dermata Therapeutics, Inc. (DRMA) rose 4.71% to USD 1.32 as of July 25, 2026 at 15:43 UTC, according to Nexqual real-time market data.
DRMA last closed at USD 1.26; the session ranged USD 1.25–1.34 on volume of 82,812 shares. Market capitalization is $5.31M, with a 52-week range of USD 1.1–7.33 (NCM). Source: Nexqual, July 25, 2026 at 15:43 UTC.
Key Statistics (as of July 25, 2026 at 15:43 UTC)
| Price | USD 1.32 |
|---|---|
| Change | ▲ 4.71% (up) |
| Previous Close | USD 1.26 |
| Open | USD 1.25 |
| Day Range | USD 1.25 – 1.34 |
| 52-Week Range | USD 1.1 – 7.33 |
| Volume | 82,812 shares |
| Market Cap | $5.31M |
| Exchange | NCM |
Technical Analysis (DRMA)
Nexqual's technical model rates DRMA "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 15:43 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.3 (neutral) |
| vs SMA50 | Above (USD 1.27) |
| MACD | 0 (positive) |
Analyst Ratings (DRMA)
Wall Street analysts rate DRMA "None" based on 1 analysts, with a mean price target of USD 4 (range USD 4–4), per Nexqual as of July 25, 2026 at 15:43 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 4 |
| High Target | USD 4 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (DRMA)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.48 vs est -0.53 ▲ beat |
| 2025-12-31 | USD -1.52 vs est -1.54 ▲ beat |
| 2025-09-30 | USD -1.65 vs est -1.59 ▼ miss |
| 2025-06-30 | USD -1.66 vs est -2.9 ▲ beat |
Source: Nexqual, July 25, 2026 at 15:43 UTC.
Financials & Fundamentals (DRMA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -103.58% |
| Current Ratio | 7.09 |
| Total Cash | $6.95M |
| Total Debt | $0 |
| Free Cash Flow | $-6.34M |
Source: Nexqual, July 25, 2026 at 15:43 UTC.
Financial Health Score (DRMA)
Nexqual rates Dermata Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $7M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -104%, ROA -52.7% |
Ownership (DRMA)
| Insider Ownership | +24.82% |
|---|---|
| Institutional Ownership | +7.38% |
| Shares Outstanding | 4.02M |
| Float | 3.17M |
| Short % of Float | +2.06% |
Source: Nexqual, July 25, 2026 at 15:43 UTC.
Leadership (DRMA)
Dermata Therapeutics, Inc. is led by Gerald T. Proehl (age 66), Founder, President, CEO & Chairman, per Nexqual as of July 25, 2026 at 15:43 UTC.
| Founder, President, CEO & Chairman | Gerald T. Proehl (age 66) |
|---|---|
| Co-Founder & Lead Independent Director | David F. Hale (age 76) |
| Senior VP & CFO | Kyri K. Van Hoose (age 47) |
| Vice President of Marketing | Kyra Peckaitis |
| Senior Vice President of Regulatory Affairs & Quality Assurance | Maria Bedoya Toro Munera (age 74) |
Major Backers & Investors (DRMA)
Notable institutional backers of Dermata Therapeutics, Inc. include Fidelity, UBS Group AG, Welch & Forbes, LLC, according to Nexqual as of July 25, 2026 at 15:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.06% |
| UBS Group AG | 0.89% |
| Welch & Forbes, LLC | 0.5% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.2% |
Source: Nexqual, July 25, 2026 at 15:43 UTC.
From Dermata Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- The combination of a proprietary harvesting protocol, developed by our exclusive supplier, and the post-harvest processing procedures, produce an ingredient that we believe optimizes the mechanical components, which are silica microstructures also called spicules, as well as the organic components of Spongilla , while eliminating any harmful bacteria that could be found in many freshwater or marine sponges.
- With our proprietary harvesting protocols and manufacturing procedures, we are able to take Spongilla lacustric raw material and leverage the combination of evolution and scientific innovation to create a unique product we like to call, Bioneedle.
- Our product development strategy is centered on the scalable use of our proprietary Bioneedle as the foundation for any well-rounded skincare routine.
- BDS works by first topically applying our proprietary sponge powder to the treatment area wherein the mechanical Bioneedles penetrate the skin, thereby creating millions of microchannels into the dermis similar to the Image 4 below.
Partnerships
- One such location is the Volga River, where we have signed an exclusive supply agreement with one of the larger known suppliers of wild harvested Spongilla raw material for our Tome skincare line, which we believe provides us with a reliable source of our supply of Spongilla raw material for the foreseeable future.
- In February 2020, we signed an exclusive supply agreement with this supplier of Spongilla raw material .
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.07 | ▼ 2.73% |
| REVB | Revelation Biosciences, Inc. | USD 1.06 | ▼ 7.83% |
| RNAZ | TransCode Therapeutics, Inc. | USD 5.93 | ▼ 29.4% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| PALI | Palisade Bio, Inc. | USD 1.95 | ▲ 2.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:43 UTC. This page is informational and not investment advice.